It is a compassionate use trial and IV therapy, so won't be that big of a hit like an outpatient oral medication. How many patients do you really think will need this for years to come, this could disappear like SARS? 50,00 patients is nothing compared to the number of people that have say lung cancer and need chemo. So, this isn't a big deal honestly in terms of revenue other than up front when hospitals add it to formulary. THen sales will taper most likely.

However, ride the wave of stupidity my friends....ride it all the way to the bank. I am telling you this as a pharmacist because using my knowledge backfires during times like this. Inverse my gut for tendies.